Clinical Trial Update: A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase II study evaluating ibrutinib in combination with FCR (fludarabine, cyclophosphamide, rituximab) in previously untreated, younger patients with chronic ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia, Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-05-15